Kevinn Eddy

Immunology and Microbiology · Life Sciences

10h-index561citations18works11.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(6), Cancer, Stress, Anesthesia, and Immune Response(6), CAR-T cell therapy research(4), Melanoma and MAPK Pathways(4), Cytomegalovirus and herpesvirus research(3)

Publications18 total

Review of: "Efficacy and Safety of CTLA-4, PD-1, and LAG-3 Immune Checkpoint Inhibitors as Monotherapy and Combination Therapy in Advanced Melanoma: A Systematic Review and Meta-Analysis"
2025Open Access
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Cancers·2024· 33 citedOpen Access
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
JID Innovations·2024· 1 citedOpen Access
Overview of current melanoma therapies
Pigment Cell & Melanoma Research·2023· 6 citedOpen Access
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study
Journal of Investigative Dermatology·2023· 5 citedOpen Access
Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression
Cells·2022· 20 citedOpen Access
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma
Cancers·2021· 16 citedOpen Access
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
Frontiers in Oncology·2021· 86 citedOpen Access
Overcoming Immune Evasion in Melanoma
International Journal of Molecular Sciences·2020· 219 citedOpen Access
778 Preclinical study using a glutamatergic signaling and immune-checkpoint inhibitors in a spontaneous melanoma prone mouse model
2020· 1 citedOpen Access
Abstract 1839: Concurrent inhibition of glutaminase (GLS) and metabotropic receptor 1 (GRM1) reduced glutamate bioavailability and led to a decrease in GRM1-expressing melanoma cell proliferation <i>in vitro</i> and tumor progression <i>in vivo</i>
Cancer Research·2019
Abstract 1839: Concurrent inhibition of glutaminase (GLS) and metabotropic receptor 1 (GRM1) reduced glutamate bioavailability and led to a decrease in GRM1-expressing melanoma cell proliferation<i>in vitro</i>and tumor progression<i>in vivo</i>
Molecular and Cellular Biology / Genetics·2019
Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma
Cancer Research·2019· 45 citedOpen Access
Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness
Oncotarget·2017· 25 citedOpen Access
Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma
Cancers·2016· 49 citedOpen Access
Genetic determination of cytomegalovirus-induced and age-related cardiopathy in inbred mice. Characterization of infiltrating cells.
PubMed·1991· 21 citedOpen Access
Cytomegalovirus infection of adipose tissues induces steatitis in adult mice.
PubMed·1990· 24 cited
Inflammatory and immunological responses to murine cytomegalovirus in resistant CBA mice
Archives of Virology·1989· 10 citedOpen Access

Frequent Co-authors

Suzie Chen(14), Raj Shah(6), Anna Fateeva(5), Mohamad Naser Eddin(4), Allison L. Isola(3), Fabian V. Filipp(3), Patricia Price(3), G. R. Shellam(3), Kajal Gupta(3), Christina Marinaro(3), Andrew Zloza(3), Simar Singh(2), Jeffrey C. Pelletier(2), Joseph Campagnolo(2), Anna Chaly(2), Katie B. Freeman(2), Philip Furmanski(2), Ann W. Silk(2), Allen B. Reitz(2), K Zembrzuski(1)